Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade.
about
Molecular and Cellular Mechanisms of Muscle Aging and Sarcopenia and Effects of Electrical Stimulation in SeniorsAnti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factorsEnteral sesame oil therapeutically relieves disease severity in rat experimental osteoarthritisPotent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases.Assessed and Emerging Biomarkers in Stroke and Training-Mediated Stroke Recovery: State of the Art.Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2.Recovery from muscle weakness by exercise and FES: lessons from Masters, active or sedentary seniors and SCI patients.Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice.Dystrophic phenotype improvement in the diaphragm muscle of mdx mice by diacerhein.Increased Circulating Levels of Interleukin-6 Induce Perturbation in Redox-Regulated Signaling Cascades in Muscle of Dystrophic Mice.Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy.Aberrant Myokine Signaling in Congenital Myotonic Dystrophy.Combined XIL-6R and urocortin-2 treatment restores MDX diaphragm muscle force.Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.STAT3 in Skeletal Muscle Function and Disorders
P2860
Q26766423-ADE203C8-631E-48BC-8B81-3C056EA078CCQ28069464-692FF8DE-72BB-4372-B558-627DCB075256Q28391067-244135A0-292F-4DC0-AFE9-9815198E540CQ30841381-EB0359F7-6A16-4778-B0DB-66D27243CC75Q33809437-7EA6F96C-B27C-48BB-946E-C7FCD0EC6806Q36900212-11B22F94-1EC6-4644-BFC1-4D03B1CE243CQ37714724-5436C5EF-B8CD-41C8-B597-EE8ED8B9631CQ38700281-A85051C5-BC68-4B58-8A22-47330991585DQ38945767-F54FF01B-61EF-42AF-AC2B-7A19EEC4C60AQ41045084-22BF18DA-EEC7-4C9C-B438-AD53B03898BCQ41282592-6ADD8300-E055-4DCC-9993-687673CBC775Q41463502-B7299D7A-3BD7-4002-96F7-A9A0CA016918Q42609904-6A7AB2CF-E524-4443-B31F-CFDA3646AF81Q42859444-770CB3E9-98B9-4AF4-B22D-EC4C715F5F31Q44925270-637D5A48-D1DA-4C65-94D4-3474F01D121AQ47949346-A106E312-8EB8-48CA-9AC1-2E5F8DAB9C03Q54116477-65F7A390-98FD-4A5D-A91D-C772D73EFA9AQ58802831-A0EF8F83-6CC5-4778-BCF2-9D9AC19A37A1
P2860
Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Functional and Morphological I ...... terleukin 6 Receptor Blockade.
@en
type
label
Functional and Morphological I ...... terleukin 6 Receptor Blockade.
@en
prefLabel
Functional and Morphological I ...... terleukin 6 Receptor Blockade.
@en
P2093
P2860
P50
P1433
P1476
Functional and Morphological I ...... nterleukin 6 Receptor Blockade
@en
P2093
Angela Catizone
Francesco Carvello
Gian Marco Moneta
Laura Pelosi
Loredana De Pasquale
Maria Grazia Berardinelli
P2860
P304
P356
10.1016/J.EBIOM.2015.02.014
P577
2015-02-26T00:00:00Z